X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare WYETH LTD with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WYETH LTD vs GLENMARK PHARMA - Comparison Results

WYETH LTD    Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WYETH LTD GLENMARK PHARMA WYETH LTD/
GLENMARK PHARMA
 
P/E (TTM) x 27.7 20.2 137.3% View Chart
P/BV x 5.3 3.6 148.1% View Chart
Dividend Yield % 1.3 0.3 381.1%  

Financials

 WYETH LTD   GLENMARK PHARMA
EQUITY SHARE DATA
    WYETH LTD
Mar-13
GLENMARK PHARMA
Mar-17
WYETH LTD/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs1,044993 105.2%   
Low Rs818729 112.2%   
Sales per share (Unadj.) Rs298.6325.5 91.7%  
Earnings per share (Unadj.) Rs57.239.3 145.7%  
Cash flow per share (Unadj.) Rs58.448.7 120.0%  
Dividends per share (Unadj.) Rs17.002.00 850.0%  
Dividend yield (eoy) %1.80.2 786.1%  
Book value per share (Unadj.) Rs249.5159.2 156.7%  
Shares outstanding (eoy) m22.72282.17 8.1%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.12.6 117.9%   
Avg P/E ratio x16.321.9 74.2%  
P/CF ratio (eoy) x15.917.7 90.1%  
Price / Book Value ratio x3.75.4 69.0%  
Dividend payout %29.75.1 583.5%   
Avg Mkt Cap Rs m21,157242,991 8.7%   
No. of employees `0000.513.0 3.8%   
Total wages/salary Rs m40016,408 2.4%   
Avg. sales/employee Rs Th13,787.47,083.9 194.6%   
Avg. wages/employee Rs Th813.01,265.4 64.3%   
Avg. net profit/employee Rs Th2,643.3855.1 309.1%   
INCOME DATA
Net Sales Rs m6,78391,857 7.4%  
Other income Rs m353374 94.4%   
Total revenues Rs m7,13692,230 7.7%   
Gross profit Rs m1,61720,367 7.9%  
Depreciation Rs m272,644 1.0%   
Interest Rs m62,373 0.2%   
Profit before tax Rs m1,93815,724 12.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-5-810 0.6%   
Tax Rs m6323,827 16.5%   
Profit after tax Rs m1,30111,088 11.7%  
Gross profit margin %23.822.2 107.5%  
Effective tax rate %32.624.3 134.1%   
Net profit margin %19.212.1 158.8%  
BALANCE SHEET DATA
Current assets Rs m6,98468,746 10.2%   
Current liabilities Rs m2,05627,027 7.6%   
Net working cap to sales %72.645.4 160.0%  
Current ratio x3.42.5 133.5%  
Inventory Days Days9985 116.8%  
Debtors Days Days2496 25.1%  
Net fixed assets Rs m24424,132 1.0%   
Share capital Rs m227282 80.5%   
"Free" reserves Rs m5,44144,643 12.2%   
Net worth Rs m5,66844,925 12.6%   
Long term debt Rs m2545,363 0.1%   
Total assets Rs m7,901117,639 6.7%  
Interest coverage x353.37.6 4,633.5%   
Debt to equity ratio x01.0 0.4%  
Sales to assets ratio x0.90.8 110.0%   
Return on assets %16.511.4 144.5%  
Return on equity %22.924.7 93.0%  
Return on capital %34.019.1 177.8%  
Exports to sales %0.20-   
Imports to sales %36.30-   
Exports (fob) Rs m15NA-   
Imports (cif) Rs m2,465NA-   
Fx inflow Rs m1556,152 0.0%   
Fx outflow Rs m2,6778,084 33.1%   
Net fx Rs m-2,66248,068 -5.5%   
CASH FLOW
From Operations Rs m9236,574 14.0%  
From Investments Rs m317-7,124 -4.4%  
From Financial Activity Rs m-4815,432 -8.9%  
Net Cashflow Rs m7591,992 38.1%  

Share Holding

Indian Promoters % 0.0 48.3 -  
Foreign collaborators % 51.1 0.0 -  
Indian inst/Mut Fund % 11.3 6.9 163.8%  
FIIs % 7.2 34.4 20.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 30.4 10.5 289.5%  
Shareholders   21,978 56,727 38.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WYETH LTD With:   IPCA LABS  SANOFI INDIA  ALEMBIC PHARMA  ORCHID PHARMA LTD  NOVARTIS  

Compare WYETH LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens 99 Points Down; Vedanta & Coal India Top Losers(09:30 am)

Asian share markets are lower today as Japanese and Hong Kong shares fall. The Nikkei 225 is off 0.9% while the Hang Seng is down 2%. The Shanghai Composite is trading down by 2.7%.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 6.6%

May 31, 2018 | Updated on May 31, 2018

For the quarter ended March 2018, GLENMARK PHARMA has posted a net profit of Rs 2 bn (down 6.6% YoY). Sales on the other hand came in at Rs 23 bn (down 7.2% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

WYETH LTD SHARE PRICE


Dec 9, 2014 (Close)

TRACK WYETH LTD

  • Track your investment in WYETH LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE WYETH LTD WITH

MARKET STATS